RXDX Prometheus Biosciences, Inc.

Ignyta, Inc., a precision oncology biotechnology company, engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases. Its products pipeline includes entrectinib, a tyrosine kinase inhibitor directed to the tropomyosin receptor kinase family tyrosine kinase receptors, ROS1, and anaplastic lymphoma kinase proteins, which is in Phase II and two Phase I clinical studies in molecularly defined adult patient populations for the treatment of solid tumors, as well as in Phase I/Ib clinical study in pediatric patients with advanced solid tumor malignancies; RXDX-105, an orally bioavailable and vascular endothelial growth factor receptor, and small molecule tyrosine kinase inhibitor of RET-driven solid tumors; and RXDX-106, a pseudo-irreversible inhibitor, which is in late preclinical development. The company was founded in 2011 and is headquartered in San Diego, California.

$25.02  +0.98 (4.06%)
As of 10/19/2021 15:56:31 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/18/2014
Outstanding shares:  38,865,986
Average volume:  83,872
Market cap:   $1,008,572,337
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    74349U108
ISIN:        US74349U1088
Sedol:      
Valuation   (See tab for details)
PE ratio:   -17.14
PB ratio:   3.31
PS ratio:   675.53
Return on equity:   -19.30%
Net income %:   -3,651.17%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy